Discovery of Benzophenanthridine Alkaloids from Zanthoxylum nitidum That Target the MDM2-p53 Axis in NSCLC

Nguyen Manh Cuong1, Elizaveta Fefilova2, Vu Thanh Loc1

  • 1Institute of Chemistry, Vietnam Academy of Science and Technology, 18 Hoang Quoc Viet, Nghia Do, Hanoi 11353, Vietnam.

Insights

Researchers identified Zanthoxylum nitidum extract and its compound nitidine as potential treatments for non-small cell lung cancer (NSCLC). These compounds target MDM2, offering a new therapeutic strategy for NSCLC, regardless of p53 status.

Area of Science:

  • Natural product chemistry
  • Cancer biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) is a major global cancer-related mortality cause.
  • Targeting the p53-MDM2 interaction is a promising strategy for NSCLC with functional p53.
  • Existing therapies have limitations, necessitating novel treatment approaches.

Purpose of the Study:

  • To screen Vietnamese ethnomedicinal plants for anticancer activity against NSCLC.
  • To identify bioactive compounds targeting the p53-MDM2 pathway.
  • To evaluate the therapeutic potential of identified compounds in NSCLC treatment.

Main Methods:

  • Screening of 33 Vietnamese plant extracts using NSCLC cell models (p53-expressing and p53-null).
  • Utilized NMR spectroscopy, molecular docking, cell cycle analysis, apoptosis assays, migration/invasion assays, PCR, immunoblotting, and Seahorse energy profiling.
  • Phytochemical analysis to identify active constituents from effective extracts.

Main Results:

  • Zanthoxylum nitidum extract showed potent, selective activity, inducing p53-dependent cell cycle arrest and apoptosis.
  • Benzophenanthridine alkaloids, particularly nitidine, were identified as active constituents with strong in silico binding to MDM2.
  • Nitidine stabilized p53 and reduced MDM2 protein levels (p53-independent), suppressed Snail, disrupted cellular bioenergetics, and inhibited NSCLC cell migration and invasion.

Conclusions:

  • Zanthoxylum nitidum and its compound nitidine are promising sources for novel NSCLC therapeutics.
  • Nitidine demonstrates efficacy irrespective of p53 mutational status, offering a broad therapeutic window.
  • These findings support the development of new MDM2-targeting drugs for NSCLC treatment.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...